Compare AbCellera Biologics Inc (ABCL) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Marsh & McLennan Companies, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Marsh & McLennan Companies, Inc. trades at $179.17 (market cap $85.76B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 36.5× AbCellera Biologics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.02% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MRSH | |
|---|---|---|
Market Cap | $2.35B | $85.76B |
Sector | Health | Financials |
52-Week High | $8.12 | $214.71 |
52-Week Low | $2.78 | $157.32 |
Enterprise Value | $1.99B | $106.60B |
Dividend Yield | — | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Marsh (MRSH) trades at $178.00, showing modest daily weakness (-0.3%) but maintaining a bullish technical trend above key support levels. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.29 exceeding expectations, and robust profitability metrics with 14.26% net income margin and 27.42% ROE. Recent acquisition of TriBridge Partners strengthens advisory capabilities while dividend payments provide shareholder returns.
Marsh presents a compelling investment case with analyst consensus target of $192.00 offering 7.9% upside potential. The stock trades at reasonable valuation multiples (P/E 21.84, P/S 3.12) for its quality profile, though rising costs and premium valuation warrant monitoring. Institutional sentiment remains positive with 11 buy ratings outweighing 1 sell recommendation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
